Chimerix (CMRX) Competitors

Fortress Biotech (NASDAQ:FBIO) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, community ranking, earnings, profitability, dividends, media sentiment and analyst recommendations.

Do insiders and institutionals hold more shares of FBIO or CMRX?

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 45.4% of Chimerix shares are owned by institutional investors. 33.4% of Fortress Biotech shares are owned by insiders. Comparatively, 13.1% of Chimerix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Do analysts prefer FBIO or CMRX?

Fortress Biotech currently has a consensus target price of $13.00, indicating a potential upside of 809.09%. Chimerix has a consensus target price of $8.50, indicating a potential upside of 888.49%. Given Chimerix's higher possible upside, analysts plainly believe Chimerix is more favorable than Fortress Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Chimerix	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor FBIO or CMRX?

Chimerix received 64 more outperform votes than Fortress Biotech when rated by MarketBeat users. Likewise, 63.62% of users gave Chimerix an outperform vote while only 63.55% of users gave Fortress Biotech an outperform vote.

Company	Underperform	Outperform
Fortress Biotech	Outperform Votes 326 63.55%	Underperform Votes 187 36.45%
Chimerix	Outperform Votes 390 63.62%	Underperform Votes 223 36.38%

Which has better valuation & earnings, FBIO or CMRX?

Fortress Biotech has higher revenue and earnings than Chimerix. Chimerix is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$84.51M	0.39	-$60.64M	-$3.05	-0.47
Chimerix	$320K	241.69	-$82.10M	-$0.94	-0.91

Is FBIO or CMRX more profitable?

Chimerix has a net margin of 0.00% compared to Fortress Biotech's net margin of -84.53%. Fortress Biotech's return on equity of 0.00% beat Chimerix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	-84.53%	N/A	-33.17%
Chimerix	N/A	-50.78%	-44.94%

Does the media favor FBIO or CMRX?

In the previous week, Chimerix had 3 more articles in the media than Fortress Biotech. MarketBeat recorded 9 mentions for Chimerix and 6 mentions for Fortress Biotech. Chimerix's average media sentiment score of 0.59 beat Fortress Biotech's score of 0.31 indicating that Chimerix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Chimerix	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, FBIO or CMRX?

Fortress Biotech has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

Summary

Fortress Biotech beats Chimerix on 9 of the 17 factors compared between the two stocks.